Supplementary Figure S2 from Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity

Abstract

<p>(A) Immunoblot analysis of AMPK and AKT in AXT cells treated with simvastatin for 12 h. The phosphorylation level of AMPK at Ser485 was not affected by simvastatin, while treatment of 1 μg/ml of insulin for 1 h (Ins) slightly enhanced phosphorylation level of AMPK at Ser485/Ser491. (B) Phase-contrast microscopy of AXT cells exposed to the indicated reagents for 20 h. (C, D) Immunoblot analysis of caspase-3 cleavage and either AMPK (B) or p38 MAPK (C) phosphorylation in AXT cells exposed to the indicated concentrations of 5-iodotubercidin or BIRB796, respectively, in the additional presence of 5 μM simvastatin for 20 h. (E) Immunoblot analysis of AMPK, p38 MAPK, and ACC phosphorylation in AXT cells treated with AICAR for 22 h. (F) Viability of AXT cells exposed to compound C in the additional presence of AICAR for 2 days. (G) Phase-contrast microscopy of AXT cells exposed to C3 transferase for 12 h.</p>